The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Rabies Vaccine for Humans-Global Market Insights and Sales Trends 2025
Synopsis
Rabies Vaccine is an immunization drug used to prevent rabies in people who have been bitten by an animal or otherwise exposed to the rabies virus.
There are a number of rabies vaccines available that are both safe and effective. They can be used to prevent rabies, before or after exposure to the rabies virus, which is commonly caused by a dog bite or a bat bite.
The global Rabies Vaccine for Humans market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Rabies Vaccine for Humans in various end use industries. The expanding demands from the Pre-exposure prophylaxis and Post-exposure prophylaxis, are propelling Rabies Vaccine for Humans market. Preventative Vaccine, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Emergency Rabies Vaccine segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Rabies Vaccine for Humans, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Rabies Vaccine for Humans market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Rabies Vaccine for Humans market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Rabies Vaccine for Humans sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Rabies Vaccine for Humans covered in this report include Novartis, Sanofi, GlaxoSmithKline, Merck, Chengda, Yisheng, Prcmise, VACN and Changsheng, etc.
The global Rabies Vaccine for Humans market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Novartis
Sanofi
GlaxoSmithKline
Merck
Chengda
Yisheng
Prcmise
VACN
Changsheng
BCHT
Hissen
Global Rabies Vaccine for Humans market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Rabies Vaccine for Humans market, Segment by Type:
Preventative Vaccine
Emergency Rabies Vaccine
Global Rabies Vaccine for Humans market, by Application
Pre-exposure prophylaxis
Post-exposure prophylaxis
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Rabies Vaccine for Humans manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Rabies Vaccine for Humans in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Rabies Vaccine is an immunization drug used to prevent rabies in people who have been bitten by an animal or otherwise exposed to the rabies virus.
There are a number of rabies vaccines available that are both safe and effective. They can be used to prevent rabies, before or after exposure to the rabies virus, which is commonly caused by a dog bite or a bat bite.
The global Rabies Vaccine for Humans market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Rabies Vaccine for Humans in various end use industries. The expanding demands from the Pre-exposure prophylaxis and Post-exposure prophylaxis, are propelling Rabies Vaccine for Humans market. Preventative Vaccine, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Emergency Rabies Vaccine segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Rabies Vaccine for Humans, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Rabies Vaccine for Humans market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Rabies Vaccine for Humans market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Rabies Vaccine for Humans sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Rabies Vaccine for Humans covered in this report include Novartis, Sanofi, GlaxoSmithKline, Merck, Chengda, Yisheng, Prcmise, VACN and Changsheng, etc.
The global Rabies Vaccine for Humans market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Novartis
Sanofi
GlaxoSmithKline
Merck
Chengda
Yisheng
Prcmise
VACN
Changsheng
BCHT
Hissen
Global Rabies Vaccine for Humans market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Rabies Vaccine for Humans market, Segment by Type:
Preventative Vaccine
Emergency Rabies Vaccine
Global Rabies Vaccine for Humans market, by Application
Pre-exposure prophylaxis
Post-exposure prophylaxis
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Rabies Vaccine for Humans manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Rabies Vaccine for Humans in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Rabies Vaccine for Humans Market Overview
1.1 Rabies Vaccine for Humans Product Overview
1.2 Rabies Vaccine for Humans Market Segment by Type
1.2.1 Preventative Vaccine
1.2.2 Emergency Rabies Vaccine
1.3 Global Rabies Vaccine for Humans Market Size by Type
1.3.1 Global Rabies Vaccine for Humans Market Size Overview by Type (2018-2029)
1.3.2 Global Rabies Vaccine for Humans Historic Market Size Review by Type (2018-2023)
1.3.3 Global Rabies Vaccine for Humans Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Rabies Vaccine for Humans Sales Breakdown by Type (2018-2023)
1.4.2 Europe Rabies Vaccine for Humans Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Rabies Vaccine for Humans Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Rabies Vaccine for Humans Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Rabies Vaccine for Humans Sales Breakdown by Type (2018-2023)
2 Global Rabies Vaccine for Humans Market Competition by Company
2.1 Global Top Players by Rabies Vaccine for Humans Sales (2018-2023)
2.2 Global Top Players by Rabies Vaccine for Humans Revenue (2018-2023)
2.3 Global Top Players by Rabies Vaccine for Humans Price (2018-2023)
2.4 Global Top Manufacturers Rabies Vaccine for Humans Manufacturing Base Distribution, Sales Area, Product Type
2.5 Rabies Vaccine for Humans Market Competitive Situation and Trends
2.5.1 Rabies Vaccine for Humans Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Rabies Vaccine for Humans Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Rabies Vaccine for Humans as of 2022)
2.7 Date of Key Manufacturers Enter into Rabies Vaccine for Humans Market
2.8 Key Manufacturers Rabies Vaccine for Humans Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Rabies Vaccine for Humans Status and Outlook by Region
3.1 Global Rabies Vaccine for Humans Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Rabies Vaccine for Humans Historic Market Size by Region
3.2.1 Global Rabies Vaccine for Humans Sales in Volume by Region (2018-2023)
3.2.2 Global Rabies Vaccine for Humans Sales in Value by Region (2018-2023)
3.2.3 Global Rabies Vaccine for Humans Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Rabies Vaccine for Humans Forecasted Market Size by Region
3.3.1 Global Rabies Vaccine for Humans Sales in Volume by Region (2024-2029)
3.3.2 Global Rabies Vaccine for Humans Sales in Value by Region (2024-2029)
3.3.3 Global Rabies Vaccine for Humans Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Rabies Vaccine for Humans by Application
4.1 Rabies Vaccine for Humans Market Segment by Application
4.1.1 Pre-exposure prophylaxis
4.1.2 Post-exposure prophylaxis
4.2 Global Rabies Vaccine for Humans Market Size by Application
4.2.1 Global Rabies Vaccine for Humans Market Size Overview by Application (2018-2029)
4.2.2 Global Rabies Vaccine for Humans Historic Market Size Review by Application (2018-2023)
4.2.3 Global Rabies Vaccine for Humans Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Rabies Vaccine for Humans Sales Breakdown by Application (2018-2023)
4.3.2 Europe Rabies Vaccine for Humans Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Rabies Vaccine for Humans Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Rabies Vaccine for Humans Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Rabies Vaccine for Humans Sales Breakdown by Application (2018-2023)
5 North America Rabies Vaccine for Humans by Country
5.1 North America Rabies Vaccine for Humans Historic Market Size by Country
5.1.1 North America Rabies Vaccine for Humans Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Rabies Vaccine for Humans Sales in Volume by Country (2018-2023)
5.1.3 North America Rabies Vaccine for Humans Sales in Value by Country (2018-2023)
5.2 North America Rabies Vaccine for Humans Forecasted Market Size by Country
5.2.1 North America Rabies Vaccine for Humans Sales in Volume by Country (2024-2029)
5.2.2 North America Rabies Vaccine for Humans Sales in Value by Country (2024-2029)
6 Europe Rabies Vaccine for Humans by Country
6.1 Europe Rabies Vaccine for Humans Historic Market Size by Country
6.1.1 Europe Rabies Vaccine for Humans Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Rabies Vaccine for Humans Sales in Volume by Country (2018-2023)
6.1.3 Europe Rabies Vaccine for Humans Sales in Value by Country (2018-2023)
6.2 Europe Rabies Vaccine for Humans Forecasted Market Size by Country
6.2.1 Europe Rabies Vaccine for Humans Sales in Volume by Country (2024-2029)
6.2.2 Europe Rabies Vaccine for Humans Sales in Value by Country (2024-2029)
7 Asia-Pacific Rabies Vaccine for Humans by Region
7.1 Asia-Pacific Rabies Vaccine for Humans Historic Market Size by Region
7.1.1 Asia-Pacific Rabies Vaccine for Humans Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Rabies Vaccine for Humans Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Rabies Vaccine for Humans Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Rabies Vaccine for Humans Forecasted Market Size by Region
7.2.1 Asia-Pacific Rabies Vaccine for Humans Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Rabies Vaccine for Humans Sales in Value by Region (2024-2029)
8 Latin America Rabies Vaccine for Humans by Country
8.1 Latin America Rabies Vaccine for Humans Historic Market Size by Country
8.1.1 Latin America Rabies Vaccine for Humans Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Rabies Vaccine for Humans Sales in Volume by Country (2018-2023)
8.1.3 Latin America Rabies Vaccine for Humans Sales in Value by Country (2018-2023)
8.2 Latin America Rabies Vaccine for Humans Forecasted Market Size by Country
8.2.1 Latin America Rabies Vaccine for Humans Sales in Volume by Country (2024-2029)
8.2.2 Latin America Rabies Vaccine for Humans Sales in Value by Country (2024-2029)
9 Middle East and Africa Rabies Vaccine for Humans by Country
9.1 Middle East and Africa Rabies Vaccine for Humans Historic Market Size by Country
9.1.1 Middle East and Africa Rabies Vaccine for Humans Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Rabies Vaccine for Humans Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Rabies Vaccine for Humans Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Rabies Vaccine for Humans Forecasted Market Size by Country
9.2.1 Middle East and Africa Rabies Vaccine for Humans Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Rabies Vaccine for Humans Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Novartis
10.1.1 Novartis Company Information
10.1.2 Novartis Introduction and Business Overview
10.1.3 Novartis Rabies Vaccine for Humans Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Novartis Rabies Vaccine for Humans Products Offered
10.1.5 Novartis Recent Development
10.2 Sanofi
10.2.1 Sanofi Company Information
10.2.2 Sanofi Introduction and Business Overview
10.2.3 Sanofi Rabies Vaccine for Humans Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Sanofi Rabies Vaccine for Humans Products Offered
10.2.5 Sanofi Recent Development
10.3 GlaxoSmithKline
10.3.1 GlaxoSmithKline Company Information
10.3.2 GlaxoSmithKline Introduction and Business Overview
10.3.3 GlaxoSmithKline Rabies Vaccine for Humans Sales, Revenue and Gross Margin (2018-2023)
10.3.4 GlaxoSmithKline Rabies Vaccine for Humans Products Offered
10.3.5 GlaxoSmithKline Recent Development
10.4 Merck
10.4.1 Merck Company Information
10.4.2 Merck Introduction and Business Overview
10.4.3 Merck Rabies Vaccine for Humans Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Merck Rabies Vaccine for Humans Products Offered
10.4.5 Merck Recent Development
10.5 Chengda
10.5.1 Chengda Company Information
10.5.2 Chengda Introduction and Business Overview
10.5.3 Chengda Rabies Vaccine for Humans Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Chengda Rabies Vaccine for Humans Products Offered
10.5.5 Chengda Recent Development
10.6 Yisheng
10.6.1 Yisheng Company Information
10.6.2 Yisheng Introduction and Business Overview
10.6.3 Yisheng Rabies Vaccine for Humans Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Yisheng Rabies Vaccine for Humans Products Offered
10.6.5 Yisheng Recent Development
10.7 Prcmise
10.7.1 Prcmise Company Information
10.7.2 Prcmise Introduction and Business Overview
10.7.3 Prcmise Rabies Vaccine for Humans Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Prcmise Rabies Vaccine for Humans Products Offered
10.7.5 Prcmise Recent Development
10.8 VACN
10.8.1 VACN Company Information
10.8.2 VACN Introduction and Business Overview
10.8.3 VACN Rabies Vaccine for Humans Sales, Revenue and Gross Margin (2018-2023)
10.8.4 VACN Rabies Vaccine for Humans Products Offered
10.8.5 VACN Recent Development
10.9 Changsheng
10.9.1 Changsheng Company Information
10.9.2 Changsheng Introduction and Business Overview
10.9.3 Changsheng Rabies Vaccine for Humans Sales, Revenue and Gross Margin (2018-2023)
10.9.4 Changsheng Rabies Vaccine for Humans Products Offered
10.9.5 Changsheng Recent Development
10.10 BCHT
10.10.1 BCHT Company Information
10.10.2 BCHT Introduction and Business Overview
10.10.3 BCHT Rabies Vaccine for Humans Sales, Revenue and Gross Margin (2018-2023)
10.10.4 BCHT Rabies Vaccine for Humans Products Offered
10.10.5 BCHT Recent Development
10.11 Hissen
10.11.1 Hissen Company Information
10.11.2 Hissen Introduction and Business Overview
10.11.3 Hissen Rabies Vaccine for Humans Sales, Revenue and Gross Margin (2018-2023)
10.11.4 Hissen Rabies Vaccine for Humans Products Offered
10.11.5 Hissen Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Rabies Vaccine for Humans Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Rabies Vaccine for Humans Industrial Chain Analysis
11.4 Rabies Vaccine for Humans Market Dynamics
11.4.1 Rabies Vaccine for Humans Industry Trends
11.4.2 Rabies Vaccine for Humans Market Drivers
11.4.3 Rabies Vaccine for Humans Market Challenges
11.4.4 Rabies Vaccine for Humans Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Rabies Vaccine for Humans Distributors
12.3 Rabies Vaccine for Humans Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
